There are 2789 resources available
1105P - Predictive factors of adverse events onset in GEPNET patients treated with PRRT
Presenter: Federica Scalorbi
Session: ePoster Display
1106P - Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms
Presenter: Timothy Price
Session: ePoster Display
1107P - Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
Presenter: Jaume Capdevila
Session: ePoster Display
1108P - Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas
Presenter: Baddar Pervaiz Butt
Session: ePoster Display
1109P - The psychological impact of COVID-19 pandemic on patients with NETs: Between resilience and vulnerability
Presenter: Eleonora Lauricella
Session: ePoster Display
1110P - COVID-19 pandemic impact on healthcare professionals treating patients with neuroendocrine tumors (NET): An international NET CONNECT survey
Presenter: Jorge Hernando
Session: ePoster Display
1111P - New prognostic frontiers for lung neuroendocrine tumors: An Italian-Spanish multicentric study of 200 cases
Presenter: Anna La Salvia
Session: ePoster Display
1112P - Modified TGR: A new strong radiological marker to accurately predict early response to PRRT in GEPNETs
Presenter: Federica Scalorbi
Session: ePoster Display
1113P - Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America
Presenter: Teodora Kolarova
Session: ePoster Display
1114P - Comparative study of combined large cell neuroendocrine carcinoma and combined small cell carcinoma in resected high-grade neuroendocrine tumors of the lung
Presenter: Yanan Wang
Session: ePoster Display